A Randomized, Double Blind Multicenter Phase 3 Study of the Efficacy, Safety, and Tolerability of 28 Weeks of Brincidofovir vs Valganciclovir for the Precention of Cytomegalovirus Disease in High Risk Kidney Allograft Recipients (303)